The U.S. Food and Drug Administration announced it has begun a safety review of the diabetes drug Actos (pioglitazone), after receiving preliminary results from a long-term observational study designed to evaluate the risk of bladder cancer associated with use of this drug.
The preliminary results are based on five-year data from an ongoing, 10-year observational study by the manufacturer, Takeda Pharmaceuticals North (more…)
The U.S. Food and Drug Administration (FDA) announced on Sept. 17 that it has begun a safety review of the diabetes drug pioglitazone (Actos) in response to early results from a long–term study to evaluate the risk of bladder cancer associated with this drug.
The preliminary results are based on five–year data from an ongoing‚ 10–year observational study by drugmaker Takeda Pharmaceuticals North America Inc. The early findings showed (more…)
A new analysis of diabetes medications Avandia (rosiglitazone) and Actos (pioglitazone) revealed that the risk of heart attack and/or heart failure, or death were the same, approximately 4%. The study has been published in the latest issue of Circulation: Cardiovascular Quality and Outcomes , an American Heart Association journal.
Takeda Pharmacuetical Co. makes Actos, while GlaxoSmithKline (GSK) makes Avandia. (more…)